Equal-WT
WhaleScore 2.0
?
OPALEYE MANAGEMENT INC.
BOSTON MA
Investment Advisor
Hedge Fund
Opaleye Management is based out of Boston. Opaleye Management is a hedge fund with 2 clients and discretionary assets under management (AUM) of $432,480,569 (Form ADV from 2024-03-26). Their last reported 13F filing for Q4 2024 included $571,422,527 in managed 13F securities
and a top 10 holdings concentration of 76.16%. Opaleye Management's largest holding is Harrow Inc with shares held of 3,990,000. Whalewisdom has at least 48 13F filings, 5 13D filings, 122 13G filings, and 141 Form 4 filings
Business Description
Opaleye Management Inc. is a Massachusetts corporation formerly named Risk/Reward Capital Management Corporation formed in 1996. Risk/Reward Capital Management Corporation name changed to Opaleye Management Inc. in 2014. James Silverman is the sole owner.
This brochure is designed solely to provide information about Opaleye for the purpose of compliance with certain obligations under the Advisers Act and, as such, responds to relevant regulatory requirements under the Advisers Act, which may differ from the information provided to potential investors in Offering Documents.
Investment Strategy
Opaleye's investment strategy involves investing in equity securities of biotechnology, specialty pharmaceutical, and medical device companies, both long and short. They focus their long investments on companies that may not be profitable yet but have the potential for significant share price growth based on their progress and financial objectives. Additionally, they actively invest in stock and derivative transactions to profit from binary events, such as clinical data milestones or FDA regulatory decisions.
Conversely, Opaleye seeks opportunities to short securities with extended valuations relative to the marketplace. They employ a research process that involves analyzing company fundamentals, such as their products, quality of management, likely catalysts, and potential competition. They may purchase securities for long-term holding, short-term gains, or very quick trades to capitalize on price swings.
Owners
- SILVERMAN, JAMES, AARON - PRESIDENT/CHIEF COMPLIANCE OFFICER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-12-31
Top Buys (13F)
| Name | % Change |
|---|---|
| ETON Eton Pharmaceuticals | 3.87% |
| CDXS Codexis Inc | 2.87% |
| TARA Protara Therapeutics | 1.17% |
| DNA Ginkgo Bioworks Hold | 0.95% |
| IMNM Immunome, Inc | 0.77% |
2024-12-31
Top Sells (13F)
| Name | % Change |
|---|---|
| KROS Keros Therapeutics, | 3.83% |
| APLT Applied Therapeutics | 1.87% |
| OCUL Ocular Therapeutix I | 0.8% |
| CYTK Cytokinetics Inc | 0.66% |
| PCVX Vaxcyte, Inc | 0.55% |
2024-12-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| HROW Harrow Inc | 23.43% |
| TGTX TG Therapeutics Inc | 11.9% |
| CDXS Codexis Inc | 7.38% |
| ETON Eton Pharmaceuticals | 6.65% |
| OCUL Ocular Therapeutix I | 6.49% |
2024-12-31
13F Activity
| Market Value | $0.57b, Prior: $0.60b |
| Inflows (Outflows) as % of Total MV | (-3.7229)% |
| New Purchases | 6 stocks |
| Added To | 13 stocks |
| Sold out of | 11 stocks |
| Reduced holdings in | 12 stocks |
| Top 10 Holdings % | 76.16% |
| Turnover %[1] | 34% |
| Turnover Alt %[2] | 7.01% |
| Time Held Top 20 | 5.9 quarters |
| Time Held Top 10 | 6.3 quarters |
| Time Held All | 7.92 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-12-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-12-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-12-31